PMID- 16475716
OWN - NLM
STAT- MEDLINE
DCOM- 20060309
LR  - 20221207
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 26
IP  - 1A
DP  - 2006 Jan-Feb
TI  - Evaluation of chemosensitivity of human bone marrow stromal cells--differences 
      between common chemotherapeutic drugs.
PG  - 347-50
AB  - BACKGROUND: Bone marrow stromal cells (BMSCs) are essential for normal 
      hematopoiesis, but also support the growth and survival of malignant 
      hematopoietic cells. There are currently no data available regarding the 
      sensitivity of BMSCs to cytotoxic drugs widely used in the therapy of 
      hematological diseases such as multiple myeloma or acute leukemia. MATERIALS AND 
      METHODS: The chemosensitivity of the BMSC line HS-5 and of primary BMSCs from 
      patients were evaluated in comparison to NCI-H929 myeloma and U937 leukemia 
      cells. RESULTS: Both HS-5 cells and human BMSCs showed substantial cell death in 
      response to chemotherapy. While alkylating agents (melphalan, treosulfan) and 
      doxorubicin demonstrated marked BMSC toxicity, nucleotide analogs (gemcitabine, 
      cytarabine) induced only limited BMSC apoptosis. CONCLUSION: Our data suggest 
      that the BMSC toxicity of cytotoxic compounds should be considered in 
      chemotherapeutic regimens.
FAU - Schmidmaier, Ralf
AU  - Schmidmaier R
AD  - Department of Hematology and Oncology, Medizinische Klinik Innenstadt, Klinikum 
      der Universitat Munchen, Munich, Germany. ralf.schmidmaier@med.uni-muenchen.de
FAU - Baumann, Philipp
AU  - Baumann P
FAU - Emmerich, Bertold
AU  - Emmerich B
FAU - Meinhardt, Gerold
AU  - Meinhardt G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 04079A1RDZ (Cytarabine)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 80168379AG (Doxorubicin)
RN  - CO61ER3EPI (treosulfan)
RN  - G1LN9045DK (Busulfan)
RN  - Q41OR9510P (Melphalan)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antimetabolites, Antineoplastic/pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Antineoplastic Agents, Alkylating/pharmacology
MH  - Bone Marrow Cells/cytology/*drug effects
MH  - Busulfan/analogs & derivatives/pharmacology
MH  - Cell Line
MH  - Cytarabine/pharmacology
MH  - Deoxycytidine/analogs & derivatives/pharmacology
MH  - Doxorubicin/pharmacology
MH  - Humans
MH  - Melphalan/pharmacology
MH  - Multiple Myeloma/drug therapy/pathology
MH  - Stromal Cells/drug effects
MH  - U937 Cells
MH  - Gemcitabine
EDAT- 2006/02/16 09:00
MHDA- 2006/03/10 09:00
CRDT- 2006/02/16 09:00
PHST- 2006/02/16 09:00 [pubmed]
PHST- 2006/03/10 09:00 [medline]
PHST- 2006/02/16 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2006 Jan-Feb;26(1A):347-50.